Search

Search Constraints

You searched for: Author/Creator Kahn, Rene

Search Results

1. 100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study. (April 2020)

2. 17.4 STRATIFICATION AND PREDICTION OF REMISSION IN FIRST-EPISODE PSYCHOSIS PATIENTS: THE OPTiMISE COHORT STUDY. (9th April 2019)

3. A polygenic risk score analysis of psychosis endophenotypes across brain functional, structural, and cognitive domains. Issue 1 (29th August 2017)

4. An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation. Issue 1 (December 2016)

5. Cortical thickness across the lifespan: Data from 17, 075 healthy individuals aged 3–90 years. Issue 1 (17th February 2021)

7. O1.7. PROTEOMIC ANALYSIS OF BLOOD BASED SAMPLES FROM THE OPTiMiSE (OPTIMIZATION OF TREATMENT AND MANAGEMENT OF SCHIZOPHRENIA IN EUROPE) STUDY POINT TOWARDS COMPLEMENT PATHWAY PROTEIN CHANGES. (1st April 2018)

8. Phase 3 Safety and Tolerability Results of the Combination Olanzapine and Samidorphan in Patients with Schizophrenia: The 1 Year ENLIGHTEN-2-Extension. (April 2021)

9. Subcortical volumes across the lifespan: Data from 18, 605 healthy individuals aged 3–90 years. Issue 1 (11th February 2021)